Evaluation of the Results of Group B Streptococcus Screening by MALDI-TOF MS among Pregnant Women in a Hungarian Hospital
Abstract
:1. Introduction
2. Results
2.1. Colonization
2.2. Antimicrobial Susceptibility Testing
2.3. ST-1 and ST-17 Detection
3. Discussion
4. Materials and Methods
4.1. Research Design and Samples
4.2. GBS Screening of Pregnant Women
4.3. MALDI-TOF MS Analysis
4.4. Antibiotic Susceptibility Testing
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Le Doare, K.; Heath, P.T. An overview of global GBS epidemiology. Vaccine 2013, 31, D7–D12. [Google Scholar] [CrossRef]
- Furfaro, L.L.; Chang, B.J.; Payne, M.S. Perinatal Streptococcus agalactiae epidemiology and surveillance targets. Clin. Microbiol. Rev. 2018, 31. [Google Scholar] [CrossRef] [Green Version]
- Baker, C. Group B streptococcal infections. In Streptococcal Infections; Stevens, D.L., Kaplan, E.L., Eds.; Oxford University Press: New York, NY, USA, 2000; pp. 222–237. [Google Scholar]
- Schrag, S.J.; Zywicki, S.; Farley, M.M.; Reingold, A.L.; Harrison, L.H.; Lefkowitz, L.B.; Hadler, J.L.; Danila, R.; Cieslak, P.R.; Schuchat, A. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N. Engl. J. Med. 2000, 342, 15–20. [Google Scholar] [CrossRef]
- Melin, P. Neonatal group B streptococcal disease: From pathogenesis to preventive strategies. Clin. Microbiol. Infect. 2011, 17, 1294–1303. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Artz, L.A.; Kempf, V.A.; Autenrieth, I.B. Rapid screening for Streptococcus agalactiae in vaginal specimens of pregnant women by fluorescent in situ hybridization. J. Clin. Microbiol. 2003, 41, 2170–2173. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brimil, N.; Barthell, E.; Heindrichs, U.; Kuhn, M.; Lütticken, R.; Spellerberg, B. Epidemiology of Streptococcus agalactiae colonization in Germany. Int. J. Med. Microbiol. 2010, 296, 39–44. [Google Scholar] [CrossRef] [PubMed]
- Jones, A.L.; Knoll, K.M.; Rubens, C.E. Identification of Streptococcus agalactiae virulence genes in the neonatal rat sepsis model using signature-tagged mutagenesis. Mol. Microbiol. 2000, 37, 1444–1455. [Google Scholar] [CrossRef]
- Caliot, É.; Dramsi, S.; Chapot-Chartier, M.P.; Courtin, P.; Kulakauskas, S.; Péchoux, C.; Trieu-Cuot, P.; Mistou, M.Y. Role of the group B antigen of Streptococcus agalactiae: A peptidoglycan-anchored polysaccharide involved in cell wall biogenesis. PLoS Pathog. 2012, 8, e1002756. [Google Scholar] [CrossRef]
- Centers for Disease Control and Prevention. Prevention of Perinatal Group B Streptococcal Disease, Revised Guidelines from CDC. MMWR 2010, 59, 1–36. [Google Scholar]
- Lartigue, M.F.; Héry-Arnaud, G.; Haguenoer, E.; Domelier, A.S.; Schmit, P.O.; van der Mee-Marquet, N.; Lanotte, P.; Mereghetti, L.; Kostrzewa, M.; Quentin, R. Identification of Streptococcus agalactiae isolates from various phylogenetic lineages by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J. Clin. Microbiol. 2009, 47, 2284–2287. [Google Scholar] [CrossRef] [Green Version]
- Cherkaoui, A.; Emonet, S.; Fernandez, J.; Schorderet, D.; Schrenzel, J. Evaluation of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for the rapid identification of beta-hemolytic streptococci. J. Clin. Microbiol. 2011, 49, 3004–3005. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lartigue, M.F.; Kostrzewa, M.; Salloum, M.; Haguenoer, E.; Héry-Arnaud, G.; Domelier, A.S.; Stumpf, S.; Quentin, R. Rapid detection of “highly virulent” Group B Streptococcus ST-17 and emerging ST-1 clones by MALDI-TOF mass spectrometry. J. Microbiol. Meth. 2011, 86, 262–265. [Google Scholar] [CrossRef] [PubMed]
- Manning, S.D.; Springman, A.C.; Lehotzky, E.; Lewis, M.A.; Whittam, T.S.; Davies, H.D. Multilocus sequence types associated with neonatal group B streptococcal sepsis and meningitis in Canada. J. Clin. Microbiol. 2009, 47, 1143–1148. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shabayek, S.; Spellerberg, B. Group B streptococcal colonization, molecular characteristics, and epidemiology. Front. Microbiol. 2018, 9, 437. [Google Scholar] [CrossRef] [PubMed]
- Bergseng, H.; Afset, J.E.; Radtke, A.; Loeseth, K.; Lyng, R.V.; Rygg, M.; Bergh, K. Molecular and phenotypic characterization of invasive group B streptococcus strains from infants in Norway 2006–2007. Clin. Microbiol. Infect. 2009, 15, 1182–1185. [Google Scholar] [CrossRef] [Green Version]
- Barcaite, E.; Bartusevicius, A.; Tameliene, R.; Kliucinskas, M.; Maleckiene, L.; Nadisauskiene, R. Prevalence of maternal group B streptococcal colonisation in European countries. Acta Obstet. Gynecol. Scand. 2008, 87, 260–271. [Google Scholar] [CrossRef]
- Gajic, I.; Plainvert, C.; Kekic, D.; Dmytruk, N.; Mijac, V.; Tazi, A.; Glaser, P.; Ranin, L.; Poyart, C.; Opavski, N. Molecular epidemiology of invasive and non-invasive group B Streptococcus circulating in Serbia. Int. J. Med. Microbiol. 2019, 309, 19–25. [Google Scholar] [CrossRef]
- Garland, S.M.; Cottrill, E.; Markowski, L.; Pearce, C.; Clifford, V.; Ndisang, D.; Kelly, N.; Daley, A.J. Antimicrobial resistance in group B streptococcus: The Australian experience. J. Med. Microbiol. 2011, 60, 230–235. [Google Scholar] [CrossRef] [Green Version]
- Nakamura, P.A.; Schuab, R.B.B.; Neves, F.P.; Pereira, C.F.; Paula, G.R.; Barros, R.R. Antimicrobial resistance profiles and genetic characterisation of macrolide resistant isolates of Streptococcus agalactiae. Mem. Inst. Oswaldo Cruz 2011, 106, 119–122. [Google Scholar] [CrossRef] [Green Version]
- De Francesco, M.A.; Caracciolo, S.; Gargiulo, F.; Manca, N. Phenotypes, genotypes, serotypes and molecular epidemiology of erythromycin-resistant Streptococcus agalactiae in Italy. Eur. J. Clin. Microbiol. Infect. Dis. 2012, 31, 1741–1747. [Google Scholar] [CrossRef]
- Morozumi, M.; Wajima, T.; Kuwata, Y.; Chiba, N.; Sunaoshi, K.; Sugita, K.; Sakata, H.; Iwata, S.; Ubukata, K. Associations between capsular serotype, multilocus sequence type, and macrolide resistance in Streptococcus agalactiae isolates from Japanese infants with invasive infections. Epidemiol. Infect. 2014, 142, 812–819. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Blaschke, A.J.; Pulver, L.S.; Korgenski, E.K.; Savitz, L.A.; Daly, J.A.; Byington, C.L. Clindamycin-resistant group B Streptococcus and failure of intrapartum prophylaxis to prevent early-onset disease. J. Pediatrics 2010, 156, 501–503. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Capanna, F.; Emonet, S.P.; Cherkaoui, A.; Irion, O.; Schrenzel, J.; Martinez de Tejada, B. Antibiotic resistance patterns among group B Streptococcus isolates: Implications for antibiotic prophylaxis for early-onset neonatal sepsis. Swiss Med. Wkly. 2013, 143, w13778. [Google Scholar] [CrossRef] [PubMed]
- Capraro, G.A.; Rambin, E.D.; Vanchiere, J.A.; Bocchini, J.A., Jr.; Matthews-Greer, J.M. High rates of inducible clindamycin resistance among prenatal group B streptococcal isolates in one northwest Louisiana academic medical center. J. Clin. Microbiol. 2013, 51, 2469. [Google Scholar] [CrossRef] [Green Version]
- Di Renzo, G.C.; Melin, P.; Berardi, A.; Blennow, M.; Carbonell-Estrany, X.; Donzelli, G.P.; Hakansson, S.; Hod, M.; Hughes, R.; Kurtzer, M.; et al. Intrapartum GBS screening and antibiotic prophylaxis: A European consensus conference. J. Matern. Fetal Neonatal Med. 2015, 28, 766–782. [Google Scholar] [CrossRef]
- Manning, S.D.; Lewis, M.A.; Springman, A.C.; Lehotzky, E.; Whittam, T.S.; Davies, H.D. Genotypic diversity and serotype distribution of group B streptococcus isolated from women before and after delivery. Clin. Infect. Dis. 2008, 46, 1829–1837. [Google Scholar] [CrossRef] [Green Version]
- Teatero, S.; McGeer, A.; Low, D.E.; Li, A.; Demczuk, W.; Martin, I.; Fittipaldi, N. Characterization of invasive group B streptococcus strains from the greater Toronto area, Canada. J. Clin. Microbiol. 2014, 52, 1441–1447. [Google Scholar] [CrossRef] [Green Version]
- Matuschek, E.; Brown, D.F.; Kahlmeter, G. Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories. Clin. Microbiol. Infect. 2014, 20, O255–O266. [Google Scholar] [CrossRef] [Green Version]
Age Groups (Years Old) | <21 | 21–25 | 26–30 | 31–35 | 36–40 | 41–45 | >45 | Total | |
---|---|---|---|---|---|---|---|---|---|
Year | |||||||||
2012 | No. of screened samples | 4 | 73 | 468 | 1037 | 823 | 357 | 114 | 2876 |
No. of GBS positive samples (colonization rate; %) | 0 (0) | 10 (13.7) | 80 (17.1) | 196 (18.9) | 150 (18.2) | 53 (14.8) | 17 (14.9) | 506 (17.6) | |
2013 | No. of screened samples | 6 | 88 | 538 | 966 | 867 | 329 | 116 | 2910 |
No. of GBS positive samples (colonization rate; %) | 1 (16.7) | 24 (27.3) | 96 (17.8) | 176 (18.2) | 142 (16.4) | 52 (15.8) | 17 (14.7) | 508 (17.5) | |
2014 | No. of screened samples | 10 | 94 | 539 | 1015 | 890 | 344 | 115 | 3007 |
No. of GBS positive samples (colonization rate; %) | 2 (20.0) | 15 (16.0) | 106 (19.7) | 212 (20.9) | 168 (18.9) | 69 (20.1) | 23 (20.0) | 595 (19.8) | |
2015 | No. of screened samples | 3 | 103 | 557 | 992 | 884 | 352 | 89 | 2980 |
No. of GBS positive samples (colonization rate; %) | 0 (0) | 16 (15.5) | 101 (18.1) | 198 (20.0) | 177 (20.0) | 67 (19.0) | 17 (19.1) | 576 (19.3) | |
2016 | No. of screened samples | 9 | 92 | 568 | 1001 | 866 | 341 | 89 | 2966 |
No. of GBS positive samples (colonization rate; %) | 2 (22.2) | 17 (18.5) | 123 (21.7) | 193 (19.3) | 160 (18.5) | 57 (16.7) | 18 (20.2) | 570 (19.2) | |
2017 | No. of screened samples | 7 | 108 | 584 | 951 | 839 | 331 | 60 | 2880 |
No. of GBS positive samples (colonization rate; %) | 1 (14.3) | 14 (13.0) | 111 (19.0) | 158 (16.6) | 147 (17.5) | 62 (18.7) | 9 (15.0) | 502 (17.4) | |
2018 | No. of screened samples | 3 | 75 | 312 | 548 | 480 | 197 | 33 | 1648 |
No. of GBS positive samples (colonization rate; %) | 0 (0) | 13 (17.3) | 59 (18.9) | 109 (19.9) | 85 (17.7) | 27 (13.7) | 4 (12.0) | 297 (18.0) | |
Total | No. of screened samples | 42 | 633 | 3566 | 6510 | 5649 | 2251 | 616 | 19267 |
No. of GBS positive samples (colonization rate; %) | 6 (14.3) | 109 (17.2) | 676 (19.0) | 1242 (19.0) | 1029 (18.2) | 387 (17.2) | 105 (17.1) | 3554 (18.5) |
Year | GBS Positive Samples | Erythromycin Resistant Strains (%) | Clindamycin Resistant Strains (%) | Strains Resistant to Erythromycin Alone (%) | Strains Resistant to Clindamycin Alone (%) | Erythromycin-Clindamycin Co-Resistant Strains (%) |
---|---|---|---|---|---|---|
2012 | 506 | 148 (29.2) | 153 (30.2) | 6 (1.2) | 11 (2.2) | 142 (28) |
2013 | 508 | 172 (33.9) | 170 (33.5) | 6 (1.2) | 4 (0.8) | 166 (32.8) |
2014 | 595 | 190 (31.9) | 182 (30.6) | 17 (2.9) | 9 (1.5) | 173 (29.1) |
2015 | 576 | 222 (38.5) | 221 (38.4) | 11 (1.9) | 10 (1.7) | 211 (36.6) |
2016 | 570 | 196 (34.4) | 182 (31.9) | 14 (2.5) | 0 (0) | 182 (31.9) |
2017 | 502 | 206 (41.0) | 206 (41.0) | 6 (1.2) | 6 (1.2) | 200 (39.8) |
2018 | 297 | 118 (39.7) | 115 (38.7) | 12 (4.0) | 9 (3.0) | 106 (35.7) |
Total | 3554 | 1239 (34.9) | 1230 (34.6) | 68 (1.9) | 49 (1.4) | 1181 (33.2) |
Sequence Type | No. of Strains Detected (%) | Erythromycin Resistant Strains (%) | Clindamycin Resistant Strains (%) | Strains Resistant to Clindamycin Alone (%) | Erythromycin-Clindamycin Co-Resistant Strains (%) |
---|---|---|---|---|---|
ST-1 | 71 (27.3) | 37 (52.1) | 37 (52.1) | 0 (0) | 37 (52.1) |
ST-17 | 50 (19.2) | 16 (32.0) | 17 (34.0) | 1 (2.0) | 16 (32.0) |
Other (non-ST-1, non-ST-17) | 139 (53.5) | 43 (30.9) | 47 (33.8) | 4 (2.9) | 43 (30.9) |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ábrók, M.; Tigyi, P.; Kostrzewa, M.; Burián, K.; Deák, J. Evaluation of the Results of Group B Streptococcus Screening by MALDI-TOF MS among Pregnant Women in a Hungarian Hospital. Pathogens 2020, 9, 1. https://doi.org/10.3390/pathogens9010001
Ábrók M, Tigyi P, Kostrzewa M, Burián K, Deák J. Evaluation of the Results of Group B Streptococcus Screening by MALDI-TOF MS among Pregnant Women in a Hungarian Hospital. Pathogens. 2020; 9(1):1. https://doi.org/10.3390/pathogens9010001
Chicago/Turabian StyleÁbrók, Marianna, Petra Tigyi, Markus Kostrzewa, Katalin Burián, and Judit Deák. 2020. "Evaluation of the Results of Group B Streptococcus Screening by MALDI-TOF MS among Pregnant Women in a Hungarian Hospital" Pathogens 9, no. 1: 1. https://doi.org/10.3390/pathogens9010001